| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/15360288.2014.997854 |
| P698 | PubMed publication ID | 25562725 |
| P2093 | author name string | Jeffrey Fudin | |
| Raymond C Boston | |||
| Oscar A Linares | |||
| William E Schiesser | |||
| Annemarie L Daly Linares | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| The analgesic activity of morphine-6-glucuronide | Q24541287 | ||
| Applications of CYP450 testing in the clinical setting | Q24621760 | ||
| An Algorithm for Least-Squares Estimation of Nonlinear Parameters | Q26778383 | ||
| Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase | Q26778389 | ||
| Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics | Q26849557 | ||
| Forensic drug testing for opiates, III. Urinary excretion rates of morphine and codeine following codeine administration | Q28244523 | ||
| Analgesic effects of codeine-6-glucuronide after intravenous administration | Q28257877 | ||
| Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide | Q28274355 | ||
| Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development | Q29013931 | ||
| The Path to Personalized Medicine | Q29541502 | ||
| Clinical pharmacokinetics (second of two parts). | Q34048590 | ||
| CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages | Q34352560 | ||
| Morphine-6-glucuronide: actions and mechanisms | Q34425978 | ||
| Computational opioid prescribing: a novel application of clinical pharmacokinetics | Q35084232 | ||
| Norepinephrine metabolism in humans. Kinetic analysis and model | Q35581544 | ||
| Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain | Q39395812 | ||
| Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. | Q39467483 | ||
| A review of metabolite kinetics | Q39842309 | ||
| Drug metabolite kinetics | Q40334906 | ||
| Morphine metabolites | Q41374991 | ||
| Codeine disposition in smokers and nonsmokers | Q41622666 | ||
| The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. | Q41823871 | ||
| A numerical deconvolution method to estimate C-peptide secretion in humans after an intravenous glucose tolerance test. | Q42452822 | ||
| Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers | Q42622823 | ||
| Codeine, ultrarapid-metabolism genotype, and postoperative death | Q43289451 | ||
| Codeine and morphine pathway | Q43480688 | ||
| Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing | Q43566770 | ||
| Codeine kinetics as determined by radioimmunoassay | Q43950213 | ||
| Is it farewell to codeine? | Q45033609 | ||
| Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics | Q45095085 | ||
| A novel minimal model to describe NEFA kinetics following an intravenous glucose challenge | Q46782316 | ||
| More codeine fatalities after tonsillectomy in North American children | Q48249814 | ||
| Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. | Q48747108 | ||
| Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. | Q51112914 | ||
| EMSA: a SAAM service for the estimation of population parameters based on model fits to identically replicated experiments. | Q52418754 | ||
| Drug therapy. Clinical Pharmacokinetics (first of two parts). | Q52867382 | ||
| Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. II: A bootstrap modification of standard two-stage (STS) method for phase I trial. | Q52911545 | ||
| Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. | Q54593894 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 4-15 | |
| P577 | publication date | 2015-01-06 | |
| P1433 | published in | Journal of Pain and Palliative Care Pharmacotherapy | Q6295706 |
| P1476 | title | CYP2D6 phenotype-specific codeine population pharmacokinetics. | |
| P478 | volume | 29 |
| Q57585515 | CYP450 genotype and pharmacogenetic association studies: a critical appraisal |
| Q88613788 | Genomics and electronic health record systems |
| Q38756015 | Personalized medicine: Genetic risk prediction of drug response |
| Q50078978 | Preoperative Genetic Testing and Personalized Medicine: Changing the Care Paradigm. |
| Q62086883 | Update of the Scientific Opinion on opium alkaloids in poppy seeds |
Search more.